Markets Stocks Economy Crypto Earnings Banking Energy
Home› Stocks› Feature
Stocks · Exclusive

Foundation Healthcare buys into dermatology in SG$17.2m deal

Foundation Healthcare buys into dermatology in SG$17.2m deal
Stocks · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Nov 20, 2026 3 min read

Singapore-listed healthcare group Foundation Healthcare is making its first move into dermatology, agreeing to buy majority stakes in two specialist clinics for SG$17.2 million in cash. The deal, announced in an SGX filing, marks a strategic expansion for the group, which currently operates across 17 specialties with about 120 practitioners.

What’s being bought?

Foundation will acquire 60% of Anaesthesia Connect and The Skin Specialists and Laser Clinic, paying SG$4.3 million and SG$12.9 million respectively. The remaining 40% of each practice will be bought later, with the final price tied to how the businesses perform financially.

The acquisition adds dermatology to Foundation’s service lineup and boosts its anesthesiology capacity, which the company says will support higher surgical volumes. The first tranche of the deal is expected to complete by the end of 2026, with the second tranche following by the end of 2029.

How the deal is structured

The later 40% purchase will be paid with a mix of cash and newly issued Foundation shares. This is a common structure known as an “earnout,” where sellers receive additional payment if the acquired businesses hit certain financial targets. It helps the buyer preserve cash and keeps the sellers motivated to perform well after the sale.

However, the share-based component creates uncertainty for investors. If the clinics perform strongly, Foundation may issue more shares, increasing the total share count. That could dilute future earnings per share (EPS), even if the company’s overall profits rise.

Foundation says the transactions should lift earnings and EPS once each tranche completes, but the exact impact depends on the size of the performance-linked payout, which won’t be known until the earnout period ends.

What it means for investors

For everyday investors, the key takeaway is that the deal’s full cost is not fixed. The SG$17.2 million upfront payment is clear, but the later payment could be larger or smaller depending on how the clinics perform. That makes it harder to assess the deal’s true value today.

Investors often view earnout structures with caution. While they can protect the buyer’s cash and align incentives, they also create an “equity overhang”—the possibility that more shares will be issued in the future, reducing the value of existing shares. This is why the market may not fully credit the company’s claim that the deal will be EPS-accretive until the details of the share-settled payout are clearer.

Foundation’s move into dermatology is part of a broader trend of healthcare groups expanding into higher-margin specialty services. Dermatology, in particular, has seen growing demand for cosmetic and medical skin treatments. The addition of anesthesiology capacity also suggests the group is preparing for more surgical procedures, which could drive revenue growth.

Still, the long timeline—completion of the first tranche in 2026 and the second in 2029—means investors will have to wait to see the full benefits. In the meantime, they should watch how the clinics perform and how Foundation manages its share issuance.

For context, healthcare stocks have been volatile recently, with healthcare stocks sliding on regulatory and legal news. But Foundation’s deal is a company-specific move, not a sector-wide event.

Investors should also note that the deal is subject to regulatory approvals and other closing conditions. If those are delayed, the timeline could shift.

Overall, this is a measured expansion for Foundation Healthcare, but the earnout structure adds a layer of complexity. As with any deal involving share-based payments, the devil is in the details—and those details won’t be fully known for several years.

More from this story

Next article · Don't miss

Samsung reshuffles memory chip leadership as AI demand drives profits

Samsung Electronics has put Hwang Sang-joon in charge of its memory chip business, a move that comes as AI data-center demand fuels a 15-fold surge in quarterly chip profit. The reshuffle signals the company's push to lock in momentum in the AI memory market.

Read the story →
Samsung reshuffles memory chip leadership as AI demand drives profits